Polaroid Therapeutics Teams Up With Ingenix.Ai To Supercharge Clinical Trials With Multimodal Agentic AI To Accelerate Advanced Patient-Centred Therapies

• The advanced AI co-pilot reduces uncertainty and inaccuracies, ultimately resulting in better, more predictable clinical trials
• The collaboration will embed multimodal and multiscale agentic AI into clinical workflows
• This partnership reflects a shared commitment to using predictive technology to simulate clinical trials and accelerate effective treatments, and transform patient lives 

Zurich, Switzerland, 24 June, 2025 - Polaroid Therapeutics (PTx), the Swiss-based biotech company, today announced its strategic partnership with Ingenix.AI, a multimodal and multiscale generative Artificial Intelligence (AI) co-pilot for clinical development. This collaboration brings together PTx’s versatile clinical research portfolio for APT^TM (Antimicrobial Polymer Technology) and Ingenix.AI’s powerful AI engine to simulate clinical trials on digital twins of the human body. Ingenix.AI’s technology allows PTx’s team to analyze data ranging from molecular to cellular and population levels to enhance its wound management clinical trial efforts. 

PTx and Ingenix.AI share a common goal in leveraging technology to improve patient outcomes. By working together, the companies will produce more accurate predictive insights that increase certainty, optimize efficiency, and expedite PTx’s mission to deliver a new generation of wound care therapies to patients who need them most. 

The cutting-edge agentic AI co-pilot for clinical development is designed to support investigators by integrating multiscale data sources, surfacing biological mechanisms, flagging risks, and streamlining positive outcomes of any future clinical trials. 

The companies are jointly exploring the potential impact on future clinical study designs and regulatory interactions. All data and insights gathered from Ingenix.AI co-pilot will be heavily scrutinized by a board of clinical experts to validate Ingenix.AI’s AI model within the existing PTx clinical workflows.

“Our partnership with Ingenix.AI marks a pivotal step in scaling and advancing how we design and deliver our clinical trials with APT^TM in wound management” comments Ran Frenkel, CEO and Co-Founder of PTx. “Our work together goes beyond AI integration into our process. It is a shared belief in leveraging technology to ultimately improve patient care and outcomes. By combining our intensive clinical research program and Ingenix.AI’s unique technology, pioneering it for the first time in the world in advanced wound management, we are developing better solutions for patients sooner. “

“We are excited to partner with Polaroid Therapeutics, as this marks a milestone in our journey - from making groundbreaking advances in AI research to delivering tangible value to the pharmaceutical industry and, ultimately, to patients,” said Piotr Surma, CEO of Ingenix. “We believe our platform, with its explainability and deep understanding of multiscale biological phenomena, will help Polaroid Therapeutics to significantly de-risk their clinical development.”